Living Life Again
On December 1, 2016, Stan Stanek of Chanhassen, Minnesota, was diagnosed with acute myeloid leukemia (AML) and told that his best chance of survival was a bone marrow transplant. a busy elementary school in Atlanta, Ga., she didn’t want those things to slow her down, so she ignored them.
Stan went through several more months of treatment, numerous bone marrow biopsies and blood infusions. Eventually, he says, “We came to the realization that chemo was just not working. I was hitting a brick wall and I didn’t really know what to do. I needed the transplant, but doctors at the Mayo Clinic [in Rochester] wouldn’t even consider it until I was in remission.”
Stan had a specific type of AML caused by a gene mutation called IDH2, found in fewer than 15% of patients with the disease, and IDHIFA was being studied in patients like him. He met all the qualifying criteria for the trial and began treatment – one IDHIFA pill daily – in July 2017.
It was not long before he noticed a change. “I seemed to be getting better. I started to feel stronger and I was having fewer blood infusions,” he says.
Six months later, after 18 trips from his Minnesota home to Houston, Stan achieved complete remission. He was cleared for a bone marrow transplant, with his brother as the donor, in February 2018.
Since it was performed, he has had several biopsies and remains in complete remission.
“I do not believe I would be here today if it weren’t for this pill,” Stan adds. “IDHIFA was the key that opened the door to my bone marrow transplant.”
Stan and Sue are celebrating their 40th wedding anniversary this year and enjoying moments they thought might be lost because of AML. “I’m doing all the things I was before,” Stan says. “For me IDHIFA wasn’t only hope, it was an answer. I’m living life again.”
The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com
430 E. 29th Street, 14FL, New York, NY 10016 • 212-546-4000
